GlassScriptPhysician profile
Lisa A Charles Fields
NPI 1952313207
$1,961.50
in general payments reported to CMS, 2019-2025
24 companies · $536 in 2025
The $536 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $649 · 2022: $152 · 2023: $275 · 2024: $349 · 2025: $536.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,160.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $311.43 | 2021-2025 | Otezla, Otezla, Repatha |
| Novo Nordisk INC | $269.18 | 2021-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $261.58 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $223.52 | 2021-2025 | Jardiance, Tradjenta |
| Lilly USA, LLC | $165.86 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $143.91 | 2021 | |
| Merck Sharp & Dohme LLC | $108.31 | 2021-2025 | Vaxneuvance, Vaxelis, Gardasil 9 |
| E.R. Squibb & Sons, L.L.C. | $64.64 | 2022-2023 | |
| Glaxosmithkline, LLC. | $64.40 | 2021-2022 | |
| Organon LLC | $59.38 | 2021-2025 | Nexplanon, Nuvaring |
| Exeltis, USA INC. | $31.16 | 2021-2024 | Slynd |
| Xeris Pharmaceuticals, INC. | $28.33 | 2022-2023 | Gvoke Hypopen |
| Biohaven Pharmaceuticals, INC. | $27.02 | 2021 | |
| Exact Sciences Corporation | $22.38 | 2025 | The Cologuard Plus Collection Kit |
| Sunovion Pharmaceuticals INC. | $21.02 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $20.91 | 2025 | |
| Amarin Pharma, INC. | $19.44 | 2021 | |
| Ars Pharmaceuticals Operations, INC. | $19.41 | 2025 | Neffy |
| Abbott Laboratories | $18.82 | 2021 | |
| Phathom Pharmaceuticals, INC. | $17.87 | 2025 | Voquezna |
| Cranial Technologies, INC | $16.63 | 2021 | |
| Phadia US INC. | $15.99 | 2022 | |
| Ironwood Pharmaceuticals, INC | $15.29 | 2021 | |
| Horizon Therapeutics Plc | $15.02 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Charles Fields listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.